Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,137.90
    +59.04 (+0.73%)
     

  • Bitcoin USD

    63,815.88
    +546.28 (+0.86%)
     

  • CMC Crypto 200

    1,330.34
    -66.20 (-4.74%)
     

  • S&P 500

    5,105.31
    +56.89 (+1.13%)
     

  • Dow

    38,213.01
    +127.21 (+0.33%)
     

  • Nasdaq

    15,948.53
    +336.77 (+2.16%)
     

  • Gold

    2,344.80
    +2.30 (+0.10%)
     

  • Crude Oil

    83.68
    +0.11 (+0.13%)
     

  • 10-Yr Bond

    4.6590
    -0.0470 (-1.00%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

George Budwell, The Motley Fool
·2-min read

Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover here appears to be the news that the Food and Drug Administration (FDA) has lifted the partial clinical hold on BCX9930. BCX9930 is an oral Factor D inhibitor indicated for a rare blood disease known as paroxysmal nocturnal hemoglobinuria (PNH).

Continue reading